Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Céline Guinet"'
Publikováno v:
Expert Review of Hematology. 6:155-164
New oral anticoagulants are directed towards a single target, essentially factor Xa (FXa) or factor IIa. They do not require routine coagulation monitoring. However, in special clinical settings (emergency surgery, bleeding, thrombosis, control of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ca7c867551df41b6af0a95077a2316
https://doi.org/10.1586/ehm.13.11
https://doi.org/10.1586/ehm.13.11
Publikováno v:
Thrombosis Research. 129:e77-e82
Introduction Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in Phase III development for prevention and treatment of thromboembolic disorders. Fondaparinux is an approved indirect FXa inhibitor. This study compared the effects of edoxaban and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb87de4659cb72ee34934505067018
https://doi.org/10.1016/j.thromres.2011.07.026
https://doi.org/10.1016/j.thromres.2011.07.026
Publikováno v:
Bio tribune magazine. 38:16-21
Deux nouveaux anticoagulants directs actifs par voie orale — Dabigatran etexilate prodrogue ou Pradaxa® inhibiteur du facteur IIa et Rivaroxaban ou Xarelto® inhibiteur du facteur Xa — ont recu en Europe et au Canada l’autorisation de mise sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44917b52e665a819a5b22fad75170579
https://doi.org/10.1007/s11834-011-0044-x
https://doi.org/10.1007/s11834-011-0044-x
Publikováno v:
Annales Pharmaceutiques Françaises. 68:359-369
Resume Apres plusieurs decennies de suprematie, les heparines (non fractionnees ou de bas poids moleculaire) et les antagonistes de la vitamine K (AVK), uniquement actifs par voie parenterale pour les premieres ou a l’origine d’une iatrogenicite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6995aa25959bee4195cdff6f57d0f28b
https://doi.org/10.1016/j.pharma.2010.08.001
https://doi.org/10.1016/j.pharma.2010.08.001
Publikováno v:
Seminars in Thrombosis and Hemostasis. 34:087-090
Argatroban, a synthetic chemical compound, and recombinant hirudin (r-hirudin) are both direct thrombin inhibitors. Their actions are reversible and irreversible, respectively. We studied the influence of these two anticoagulants on the thrombin gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::751340ee8e75e871c5a96fa88caba437
https://doi.org/10.1055/s-0028-1086087
https://doi.org/10.1055/s-0028-1086087
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:2554-2556
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab36dfd1d38d4ba3d70a94d2ac5c4786
https://doi.org/10.1111/j.1538-7836.2007.02753.x
https://doi.org/10.1111/j.1538-7836.2007.02753.x
Autor:
Theodore E. Spiro, Jean Luc Martinoli, Genevieve Contant, Elisabeth Perzborn, Gabriele Rohde, Meyer Michel Samama, Céline Guinet, Yves Gourmelin, Léna Le Flem
Publikováno v:
Thrombosis Journal
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbb14c1e3b8e5f30bcbf7e92ab2ae69
https://pubmed.ncbi.nlm.nih.gov/23822763
https://pubmed.ncbi.nlm.nih.gov/23822763
Publikováno v:
Journal of thrombosis and thrombolysis. 35(2)
No routine coagulation laboratory test is recommended during rivaroxaban or dabigatran treatment. However measuring drug concentration and/or anticoagulant activity can be desirable in some special clinical settings, such as bleeding, thrombosis recu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::511b37ffa054f0988d756095fdfe7f54
https://pubmed.ncbi.nlm.nih.gov/23335022
https://pubmed.ncbi.nlm.nih.gov/23335022
Publikováno v:
Thrombosis research. 130
Although no laboratory monitoring is needed for new anticoagulants, the measurement of their activity is required in special clinical situations. Standardised tests have been developed for rivaroxaban and dabigatran which allow the measurement of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06894fdeb847a0c1c8fb84cc6d6b9259
https://pubmed.ncbi.nlm.nih.gov/23026675
https://pubmed.ncbi.nlm.nih.gov/23026675
Autor:
Meyer Michel, Samama, Genevieve, Contant, Theodore E, Spiro, Elisabeth, Perzborn, Lena Le, Flem, Céline, Guinet, Yves, Gourmelin, Jean Luc, Martinoli, W, Wijns
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 18(2)
This study evaluated the prothrombin time (PT) assay for the measurement of plasma concentrations of rivaroxaban using calibrators and controls. The intra- and interlaboratory precision of the measurement was investigated in a field trial involving 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dadd9fd84e33fa5e5ddc383b2ba2ff
https://pubmed.ncbi.nlm.nih.gov/22387577
https://pubmed.ncbi.nlm.nih.gov/22387577